Ito Haruki, Negoro Hiromitsu, Kono Jin, Hayata Naoki, Miura Takayoshi, Manabe Yumi, Miyazaki Yu, Mishina Mutsuki, Woo Je Tae, Sakane Naoki, Okuno Hiroshi
Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan.
Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.
J Clin Med. 2023 Apr 7;12(8):2757. doi: 10.3390/jcm12082757.
Nobiletin and tangeretin (NoT) are flavonoids derived from the peel of , and they have been found to modulate circadian rhythms. Because nocturia can be considered a circadian rhythm disorder, we investigated the efficacy of NoT for treating nocturia. A randomized, placebo-controlled, double-blind, crossover study was conducted. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051180071). Nocturia patients aged ≥50 years who presented nocturia more than 2 times on a frequency-volume chart were recruited. Participants received NoT or a placebo (50 mg once daily for 6 weeks), followed by a washout period of ≥2 weeks. The placebo and NoT conditions were then switched. Changes in nocturnal bladder capacity (NBC) were the primary endpoint, and changes in nighttime frequency and nocturnal polyuria index (NPi) were secondary endpoints. Forty patients (13 women) with an average age of 73.5 years were recruited for the study. Thirty-six completed the study, while four withdrew. No adverse events directly related to NoT were observed. NoT had little effect on NBC compared with the placebo. In contrast, NoT significantly changed nighttime frequency by -0.5 voids compared with the placebo ( = 0.040). The change in NPi from baseline to the end of NoT was significant (-2.8%, = 0.048). In conclusion, NoT showed little change in NBC but resulted in decreased nighttime frequency with a tendency toward reduced NPi.
川陈皮素和橘皮素(NoT)是从柑橘皮中提取的黄酮类化合物,已发现它们可调节昼夜节律。由于夜尿症可被视为一种昼夜节律紊乱,我们研究了NoT治疗夜尿症的疗效。进行了一项随机、安慰剂对照、双盲、交叉研究。该试验已在日本临床试验注册中心(jRCTs051180071)注册。招募了年龄≥50岁、在频率-容量图表上夜尿次数超过2次的夜尿症患者。参与者接受NoT或安慰剂(每日一次,每次50 mg,共6周),随后有≥2周的洗脱期。然后切换安慰剂和NoT治疗条件。夜间膀胱容量(NBC)的变化是主要终点,夜间排尿频率和夜间多尿指数(NPi)的变化是次要终点。40名患者(13名女性)平均年龄73.5岁被纳入研究。36名患者完成了研究,4名退出。未观察到与NoT直接相关的不良事件。与安慰剂相比,NoT对NBC影响不大。相比之下,与安慰剂相比,NoT使夜间排尿频率显著减少0.5次(P = 0.040)。从基线到NoT治疗结束时NPi的变化具有显著性(-2.8%,P = 0.048)。总之,NoT对NBC变化不大,但导致夜间排尿频率降低,NPi有降低趋势。